![Florian Vogl](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Florian Vogl
Technik-/Wissenschafts-/F&E-Leiter bei IMMUTEP LIMITED
Profil
Florian D.
Vogl is currently the Chief Medical Officer at Immutep Ltd.
He previously worked as the Head of Clinical Development Europe at Rainier Therapeutics, Inc. and as the Chief Medical Officer at Cellestia Biotech AG.
Dr. Vogl obtained a doctorate degree from Ludwig-Maximilians-Universität München.
Aktive Positionen von Florian Vogl
Unternehmen | Position | Beginn |
---|---|---|
IMMUTEP LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2023 |
Ehemalige bekannte Positionen von Florian Vogl
Unternehmen | Position | Ende |
---|---|---|
Rainier Therapeutics, Inc.
![]() Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Corporate Officer/Principal | - |
Cellestia Biotech AG
![]() Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Florian Vogl
Ludwig-Maximilians-Universität München | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
IMMUTEP LIMITED | Health Technology |
Private Unternehmen | 2 |
---|---|
Cellestia Biotech AG
![]() Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Rainier Therapeutics, Inc.
![]() Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |